Добірка наукової літератури з теми "Thrombolytic Agent"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Thrombolytic Agent".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Thrombolytic Agent"
Madonov, Pavel, Stanialav Leont’ev, Sergey Zotov, Maksim Ufimtsev, Svetlana Mishenina, and Dmitrii Kinsht. "Initial Results of Oral Thrombolytic Agent Clinical Application." Proceedings 2, no. 9 (July 20, 2018): 530. http://dx.doi.org/10.3390/proceedings2090530.
Повний текст джерелаAgnelli, G., MR Buchanan, F. Fernandez, J. Van Ryn, and J. Hirsh. "Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits." Blood 66, no. 2 (August 1, 1985): 399–401. http://dx.doi.org/10.1182/blood.v66.2.399.399.
Повний текст джерелаAgnelli, G., MR Buchanan, F. Fernandez, J. Van Ryn, and J. Hirsh. "Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits." Blood 66, no. 2 (August 1, 1985): 399–401. http://dx.doi.org/10.1182/blood.v66.2.399.bloodjournal662399.
Повний текст джерелаQu, Shu, and Xingwei Ding. "Shear-, Sound-, and Light-Sensitive Nanoparticles for Thrombolytic Drug Delivery." Seminars in Thrombosis and Hemostasis 46, no. 05 (May 16, 2019): 587–91. http://dx.doi.org/10.1055/s-0039-1688490.
Повний текст джерелаBizjak, Eric D., and Vincent F. Mauro. "Thrombolytic Therapy: A Review of Its Use in Acute Myocardial Infarction." Annals of Pharmacotherapy 32, no. 7-8 (July 1998): 769–84. http://dx.doi.org/10.1345/aph.17350.
Повний текст джерелаNikitin, Dmitri, Seungbum Choi, Jan Mican, Martin Toul, Wi-Sun Ryu, Jiri Damborsky, Robert Mikulik, and Dong-Eog Kim. "Development and Testing of Thrombolytics in Stroke." Journal of Stroke 23, no. 1 (January 31, 2021): 12–36. http://dx.doi.org/10.5853/jos.2020.03349.
Повний текст джерелаVerhaeghe, Raymond. "Thrombolysis in Arterial Occlusion." Thrombosis and Haemostasis 82, S 01 (1999): 109–11. http://dx.doi.org/10.1055/s-0037-1615565.
Повний текст джерелаRingleb, Peter, Robert Stingele, and Werner Hacke. "Thrombolysis in Acute Cerebrovascular Disease: Indications and Limitations." Thrombosis and Haemostasis 82, no. 08 (1999): 983–86. http://dx.doi.org/10.1055/s-0037-1615942.
Повний текст джерелаPerkins, W. R., D. E. Vaughan, S. R. Plavin, W. L. Daley, J. Rauch, L. Lee, and A. S. Janoff. "Streptokinase Entrapment in Interdigitation-Fusion Liposomes Improves Thrombolysis in an Experimental Rabbit Model." Thrombosis and Haemostasis 77, no. 06 (1997): 1174–78. http://dx.doi.org/10.1055/s-0038-1656133.
Повний текст джерелаKim, Dongjune, Susan M. Shea, and David N. Ku. "Lysis of arterial thrombi by perfusion of N,N’-Diacetyl-L-cystine (DiNAC)." PLOS ONE 16, no. 2 (February 25, 2021): e0247496. http://dx.doi.org/10.1371/journal.pone.0247496.
Повний текст джерелаДисертації з теми "Thrombolytic Agent"
Björklund, Erik. "Early risk stratification, treatment and outcome in ST-elevation myocardial infarction /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6050.
Повний текст джерелаGruber, Matthew J. "Ultraharmonic and Broadband Cavitation Thresholds for Ultrasound Contrast Agents in an In-Vitro Flow Model." University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1428066108.
Повний текст джерелаYu, Xinge. "Stroke Study: Novel Animal Models and Innovative Treatment Strategy." Ohio University / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1450735023.
Повний текст джерелаFarret, Neto Abdo. "Utiliza??o intraco?gulo de espuma fibrinol?tica - prepara??o, caracteriza??o e atividade in vitro de uma espuma de estreptoquinase e proposta de uma nova abordagem terap?utica." Universidade Federal do Rio Grande do Norte, 2014. http://repositorio.ufrn.br:8080/jspui/handle/123456789/13868.
Повний текст джерелаFoam was developed as a novel vehicle for streptokinase with the purpose of increasing the contact time and area between the fibrinolytic and the target thrombus, which would lead to a greater therapeutic efficacy at lower doses, decreasing the drug s potential to cause bleeding. Fibrinolytic foams were prepared using CO2 and human albumin (at different v:v ratios), as the gas and liquid phases, respectively, and streptokinase at a low total dose (100,000 IU) was used as fibrinolytic agent conveyed in 1 mL of foam and in isotonic saline solution. The foams were characterized as foam stability and apparent viscosity. The thrombolytic effect of the streptokinase foam was determined in vitro as thrombus lysis and the results were compared to those of a fibrinolytic solution (prepared using the same dose of streptokinase) and foam without the fibrinolytic. In vitro tests were conducted using fresh clots were weighed and placed in test tubes kept at 37 ? C. All the samples were injected intrathrombus using a multiperforated catheter. The results showed that both foam stability and apparent viscosity increased with the increase in the CO2:albumin solution ratio and therefore, the ratio of 3:1 was used for the incorporation of streptokinase. The results of thrombus lysis showed that the streptokinase foam presented the highest thrombolytic activity (44.78 ? 9.97%) when compared to those of the streptokinase solution (32.07 ? 3.41%) and the foam without the drug (19.2 ? 7.19%). We conclude that fibrinolytic foam showed statistically significant results regarding the enhancement of the lytic activity of streptokinase compared to the effect of the prepared saline solution, thus it can be a promising alternative in the treatment of thrombosis. However, in vivo studies are needed in order to corroborate the results obtained in vitro
Uma espuma foi desenvolvida como novo ve?culo para a estreptoquinase com vistas a aumentar a ?rea de contato e o tempo de perman?ncia junto ao trombo, de modo a se obter maior efici?ncia terap?utica em doses menores, diminuindo suas potenciais complica??es hemorr?gicas. A espuma fibrinol?tica foi preparada com CO2, albumina humana e estreptoquinase, em dispositivo desenvolvido para tal fim, com diferentes raz?es de fases g?s/l?quido. Ensaios de estabilidade e viscosidade aparente foram realizados para caracteriza??o das espumas e a escolha da mais est?vel. A estreptoquinase em dose total reduzida (100.000 UI) foi utilizada como fibrinol?tico veiculado em 1 mL de espuma e em solu??o salina isot?nica (0,9%). A espuma sem fibrinol?tico tamb?m foi utilizada como comparativo. Testes in vitro foram realizados utilizando-se co?gulos frescos, que foram pesados e colocados em tubos de ensaio mantidos a 37?C. As espumas com e sem fibrinol?tico e a solu??o fibrinol?tica foram testadas por aplica??o intraco?gulo em doses id?nticas atrav?s de cateter multiperfurado e pistola de inje??o. Os resultados in vitro evidenciaram atrav?s da diminui??o dos pesos dos co?gulos, que a espuma trombol?tica apresentou atividade l?tica de 44,78 ? 9,97%, enquanto as mesmas doses da estreptoquinase em solu??o salina isot?nica promoveram 32,07 ?3,41% de lise dos co?gulos. Na espuma sem fibrinol?tico a redu??o do trombo foi de 19,2 ? 7,19%. Conclui-se que a espuma fibrinol?tica apresentou resultados estatisticamente significativos no tocante ? potencializa??o da atividade l?tica da estreptoquinase, quando comparado ao efeito da solu??o preparada com solu??o salina, podendo ser uma alternativa promissora nos tratamentos das tromboses. Os dados obtidos sinalizam para necessidade de estudos in vivo para comprova??o dos obtidos nos in vitro
Evaristo, Eli Faria. "Tratamento trombolítico intravenoso no acidente vascular cerebral isquêmico: experiência da clínica neurológica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-27042007-131655/.
Повний текст джерелаIntravenous use of tissue plasminogen activator has been approved for acute ischemic stroke treatment for some years and guidelines and recommendations about its use have been published. Hospital attendance needs to be organized in order to become this treatment feasible and safe, reaching the expected results. The objective of this study was verify feasibility and safety of intravenous thrombolytic therapy in patients who were treated at Neurology Department of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo as well evaluating characteristics of these patients, their clinical outcome, complications of therapy and outcome predictors. Hospital attendance performance was also evaluated through time analysis of several steps of attendance in four different patient groups based on the place of the first medical attendance. Fifty one patients were treated between June 1998 and August 2005, primarily attended at Neurology Emergency Department (22 patients), Heart Institute (22 patients) and wards of Central Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (3 patients) as well at University Hospital (4 patients). Attendance times, represented by its median were: between symptoms onset and hospital admission (55 minutes); between hospital admission and computed cranial tomography analysis (35 minutes); between hospital admission and thrombolytic therapy onset (90 minutes) and between symptoms onset and thrombolytic therapy onset (160 minutes). As a general rule, hospital attendance performance improved during study period. However, comparative analysis of groups disclosed that time between hospital admission and computed cranial tomography analysis as well time between hospital admission and thrombolytic therapy onset were longer at Heart Institute (p = 0,002 and p = 0,01, respectively) than at Neurology Emergency Department and University Hospital. The main acute ischemic stroke mechanism was cardiac emboli (54%). Most of treated patients arrived at hospital with serious neurologic impairment (NIH Stroke Scale median 17). Excellent functional outcome in 3 months, defined as scoring 0 or 1 by modified Rankin Scale was observed in 29% and symptomatic cerebral hemorrhage in 6% of the cases. In conclusion, intravenous thrombolytic therapy with tissue plasminogen activator at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo was feasible and safe. The intensity of the neurological impairment at hospital admission, as measured by NIH Stroke Scale, and four-point or more score reduction on this scale at 24 hours were independent outcome predictors.
SMITH, DENISE ANNE BUSH. "In vitro Characterization of Echogenic Liposomes (ELIP) for Ultrasonic Delivery of Recombinant Tissue-type Plasminogen Activator (rt-PA)." University of Cincinnati / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1214234148.
Повний текст джерелаКниги з теми "Thrombolytic Agent"
Kotb, Essam. Fibrinolytic bacterial enzymes with thrombolytic activity. Heidelberg: Springer, 2012.
Знайти повний текст джерелаA, Mousa Shaker, ed. Anticoagulants, antiplatelets, and thrombolytics. Totowa, N.J: Humana Press, 2004.
Знайти повний текст джерелаAnticoagulants, antiplatelets, and thrombolytics. 2nd ed. New York, NY: Humana, 2010.
Знайти повний текст джерела1927-, Sasahara Arthur A., and Loscalzo Joseph, eds. New therapeutic agents in thrombosis and thrombolysis. 2nd ed. New York: M. Dekker, 2003.
Знайти повний текст джерелаTaylor, George Jesse. Thrombolytic therapy for acute myocardial infarction. Boston: Blackwell Scientific Publications, 1992.
Знайти повний текст джерелаJ, Del Zoppo Gregory, Mori Etsuro 1951-, and Hacke W. 1948-, eds. Thrombolytic therapy in acute ischemic stroke II. Berlin: Springer-Verlag, 1993.
Знайти повний текст джерелаC, Becker Richard, ed. The modern era of coronary thrombolysis. Boston: Kluwer Academic Publishers, 1994.
Знайти повний текст джерелаMorganroth, Joel, and E. Neil Moore, eds. Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-1605-3.
Повний текст джерелаJoel, Morganroth, and Moore E. Neil, eds. Risk/benefit analysis for the use and approval of thrombolytic, antiarrhythmic, and hypolipidemic agents: Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988. Boston: Kluwer Academic Publishers, 1989.
Знайти повний текст джерелаAntithrombotic drug therapy in cardiovascular disease. Dordrecht: Springer, 2010.
Знайти повний текст джерелаЧастини книг з теми "Thrombolytic Agent"
Rafeeq, Hamza, Muhammad Anjum Zia, Asim Hussain, Ayesha Safdar, Muhammad Bilal, and Hafiz M. N. Iqbal. "Role of Streptokinase as a Thrombolytic Agent for Medical Applications." In Industrial Applications of Microbial Enzymes, 271–93. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003202998-14.
Повний текст джерелаAgersborg, H. P. K., and J. Latts. "Is It Practical to Develop a Class III Antiarrhythmic Agent?" In Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents, 157–66. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-1605-3_11.
Повний текст джерелаOstermann, H., and U. Schmitz-Huebner. "Thrombolytic agents." In Electrocardiography and Cardiac Drug Therapy, 332–51. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1081-2_24.
Повний текст джерелаVerstraete, M. "The Hunt for the Ideal Thrombolytic Agent: Mutants of tPA and uPA, Chimera of Both Molecules, Fibrolase." In Handbook of Experimental Pharmacology, 493–520. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56637-0_19.
Повний текст джерелаZeymer, Uwe, and Karl-Ludwig Neuhaus. "New Thrombolytic Agents." In Contemporary Cardiology, 243–65. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-731-4_10.
Повний текст джерелаCollen, D., and H. R. Lijnen. "New Generation Thrombolytic Agents." In Developments in Cardiovascular Medicine, 15–26. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2618-6_2.
Повний текст джерелаMatsuo, O. "New Thrombolytic Agents: Basic Development." In Thrombolytic Therapy in Acute Ischemic Stroke III, 182–87. Tokyo: Springer Japan, 1995. http://dx.doi.org/10.1007/978-4-431-68459-6_21.
Повний текст джерелаAdgey, A. A. J., and J. A. Purvis. "Bolus Administration of Thrombolytic Agents." In Update in Intensive Care and Emergency Medicine, 27–33. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-84423-2_4.
Повний текст джерелаVerstraete, M. "Perspectives on Newer Thrombolytic Agents." In Limitation of Infarct Size, 147–55. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73585-1_17.
Повний текст джерелаSummaria, Louis. "The Biochemistry of Thrombolytic Agents." In Acute Coronary Care, 61–66. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-3828-4_7.
Повний текст джерелаТези доповідей конференцій з теми "Thrombolytic Agent"
Loscalzo, J. "THE EFFICACY AND RELATIVE FIBRIN SELECTIVITY OF PROUROKINASE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643573.
Повний текст джерелаBossaert, L., H. Demey, L. Colemont, and H. HRM. "PREHOSPITAL THROMBOLYTIC TREATMENT: A FEASIBILITY STUDY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642982.
Повний текст джерелаDel Zoppo, G. J., S. M. Otis, J. Zyroff, W. Hacke, H. Zeumer, and L. A. Harker. "INTRA-ARTERIAL THROMBOLYTIC THERAPY IN ACUTE MIDDLE CEREBRAL ARTERY STROKE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643891.
Повний текст джерелаTakada, Y., Y. Sugawara, Y. Makino, and A. Takada. "KINETIC ANALYSES OF THE ACTIVATION OF GLU- OR LYS-PLASMINOGEN BY STREPTOKINASE IN THE PRESENCE OF FIBRIN OR ITS DEGRADATION PRODUCTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644419.
Повний текст джерелаPilger, E. J., J. Lammer, H. Bertuch, and H. Steiner. "INTRAARTERIAL THROMBOLYSIS BY STREPTOKINASE-GLU-PLASMINOGEN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643002.
Повний текст джерелаQuertermous, T., J. M. Schnee, M. S. Runge, G. R. Matsueda, N. W. Hudson, J. G. Seidman, and E. Haber. "EXPRESSION OF A RECOMBINANT ANTIBODY-TARGETED THROMBOLYTIC MOLECULE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644616.
Повний текст джерелаVogel, G., and M. Machulik. "THROMBOLYTIC EFFECTS OF A POLYANIONIC COMPOUND (PENTOSAN POLYSULPHATE SP54 ) IN GERIATRIC PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643038.
Повний текст джерелаMukhametova, L., R. Aisina, K. Gerchkovich, and E. Ivanova. "Reducing the Side Effects of Thrombolytic Agent by Regulating its Release Rate from Microcapsules." In 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680193.
Повний текст джерелаStassen, J. M., and D. Collen. "ON THE MECHANISM OF THE IN VIVO SYNERGISM BETWEEN TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (scu-PA)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643793.
Повний текст джерелаHaigwood, N., E.-P. Pâques, G. Mullenbach, G. Moore, L. DesJardin, and A. Tabrizi. "IMPROVEMENT OF T-PA PROPERTIES BY MEANS OF SITE DIRECTED MUTAGENESIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643841.
Повний текст джерела